Emmaus Life Sciences reports record Q2 net revenue of $10.8M; posts $3.3M income from operations

Emmaus Life Sciences, Inc.

2023-Q2 EPS reported -$0.10 vs consensus -$0.03 ▼ miss (-226.8%)

Q2 net revenue $10.8M (up 151% YoY); six-month net revenue $17.5M (up 133% YoY).
Q2 income from operations $3.3M vs loss of $1.4M in Q2 2022; six-month income $2.2M vs loss of $4.5M.
Net loss narrowed to $1.5M ($0.03/sh) from $8.9M ($0.18/sh) in Q2 2022; six-month loss $5.0M ($0.10) vs $10.4M ($0.21).
Sales growth driven by $4.1M increase in MENA region in Q2; U.S. sales also recovering.
Cash and equivalents $1.4M at June 30, 2023, down from $2.0M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emmaus Life Sciences, Inc. reported three and six months ended June 30, 2023 results: revenue $10.8 million and $17.5 million, net income net loss of $1.5 million, or $0.03 per share, EPS $0.03 per share.

Period: three and six months ended June 30, 2023
Revenue: $10.8 million and $17.5 million
Net income: net loss of $1.5 million, or $0.03 per share
EPS: $0.03 per share
Result: reported results

Exact text from the filing

Net revenues for the three months and six months ended June 30, 2023 were $10.8 million and $17.5 million, respectively

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-066904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.